Global Hormone Refractory Prostate Cancer (HRPCA) Market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 3.2 billion by 2030 from USD 2.4 billion in 2018. The market is driven by factors such as increasing incidence of prostate cancer and rising awareness about the disease among people, which are expected to drive the demand for HRPCA treatment globally.
The global HRPCA market is segmented on the basis of type, application and region. On the basis of type, it can be classified into chemotherapy, hormonal therapy, immunotherapy and radiation therapy whereas on the basis of application it can be classified into hospitals and ambulatory surgical centers or specialty clinics. The global HRPCA market has been segmented on regional level into North America (US, Canada), Latin America (Brazil), Europe (Germany), Asia Pacific (China) and Middle East & Africa (Saudi Arabia).
Some Of The Growth Factors Of This Market:
- The number of people diagnosed with prostate cancer is expected to increase by more than 50% in the next 20 years.
- The incidence of HRPCA is expected to increase as well, due to the aging population and increased use of prostate-specific antigen (PSA) screening tests.
- HRPCA is a rare form of prostate cancer that does not respond to hormone therapy, which has been used for decades as a treatment for other forms of prostate cancer.
- There are no FDA-approved treatments for HRPCA.
- As a result, there are few clinical trials being conducted on this type of cancer.
Industry Growth Insights published a new data on “Hormone Refractory Prostate Cancer (HRPCA) Market”. The research report is titled “Hormone Refractory Prostate Cancer (HRPCA) Market research by Types (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery), By Applications (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), By Players/Companies Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG, Johnson & Johnson”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hormone Refractory Prostate Cancer (HRPCA) Market Research Report
By Type
Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
By Application
Hospitals, Ambulatory Surgical Centers, Specialty Clinics
By Companies
Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG, Johnson & Johnson
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global Hormone Refractory Prostate Cancer (HRPCA) Market Report Segments:
The global Hormone Refractory Prostate Cancer (HRPCA) market is segmented on the basis of:
Types
Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Specialty Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Inc
- Sanofi S.A
- Dendreon Corporation, Bayer AG
- Johnson & Johnson
 Market Overview.svg)
Highlights of The Hormone Refractory Prostate Cancer (HRPCA) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Hormonal Therapy
- Immunotherapy
- Radiation Therapy
- Surgery
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hormone Refractory Prostate Cancer (HRPCA) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hormone refractory prostate cancer (HRPCA) is a type of prostate cancer that does not respond to hormone therapy.
Some of the key players operating in the hormone refractory prostate cancer (hrpca) market are Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG, Johnson & Johnson.
The hormone refractory prostate cancer (hrpca) market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hormone Refractory Prostate Cancer (HRPCA) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hormone Refractory Prostate Cancer (HRPCA) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hormone Refractory Prostate Cancer (HRPCA) Market - Supply Chain
4.5. Global Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
4.5.1. Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hormone Refractory Prostate Cancer (HRPCA) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hormone Refractory Prostate Cancer (HRPCA) Market Absolute $ Opportunity
5. Global Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Type
5.3.1. Chemotherapy
5.3.2. Hormonal Therapy
5.3.3. Immunotherapy
5.3.4. Radiation Therapy
5.3.5. Surgery
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Centers
6.3.3. Specialty Clinics
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hormone Refractory Prostate Cancer (HRPCA) Demand Share Forecast, 2019-2026
9. North America Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Ambulatory Surgical Centers
9.4.3. Specialty Clinics
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Type
9.7.1. Chemotherapy
9.7.2. Hormonal Therapy
9.7.3. Immunotherapy
9.7.4. Radiation Therapy
9.7.5. Surgery
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hormone Refractory Prostate Cancer (HRPCA) Demand Share Forecast, 2019-2026
10. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Specialty Clinics
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Type
10.7.1. Chemotherapy
10.7.2. Hormonal Therapy
10.7.3. Immunotherapy
10.7.4. Radiation Therapy
10.7.5. Surgery
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hormone Refractory Prostate Cancer (HRPCA) Demand Share Forecast, 2019-2026
11. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Specialty Clinics
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Sie and Volume Forecast by Type
11.7.1. Chemotherapy
11.7.2. Hormonal Therapy
11.7.3. Immunotherapy
11.7.4. Radiation Therapy
11.7.5. Surgery
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hormone Refractory Prostate Cancer (HRPCA) Demand Share, 2019-2026
12. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Specialty Clinics
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Type
12.7.1. Chemotherapy
12.7.2. Hormonal Therapy
12.7.3. Immunotherapy
12.7.4. Radiation Therapy
12.7.5. Surgery
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Demand Share, 2019-2026
13. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Specialty Clinics
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size and Volume Forecast by Type
13.7.1. Chemotherapy
13.7.2. Hormonal Therapy
13.7.3. Immunotherapy
13.7.4. Radiation Therapy
13.7.5. Surgery
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hormone Refractory Prostate Cancer (HRPCA) Market: Market Share Analysis
14.2. Hormone Refractory Prostate Cancer (HRPCA) Distributors and Customers
14.3. Hormone Refractory Prostate Cancer (HRPCA) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Astellas Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi S.A
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Dendreon Corporation, Bayer AG
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
